Why the study?
Does percutaneous pulmonary valve implantation improve hemodynamics in children with dysfunctional surgically implanted bioprosthetic valves in the RVOT?
Population
14 children, median age 14.7 years, median weight 57.8 kg, with dysfunctional surgically implanted…
Design
Cohort
Follow-up
mean 12.9 +/- 9.8 months
Key result
Percutaneous pulmonary valve implantation in dysfunctional bioprosthetic valves significantly reduced right ventricular pressure from 82.2 to 59.4 mmHg (P<0.001) at 24 hours.
Authors
Loading...
Supports PPVI feasibility in dysfunctional bioprosthetic pulmonary valves in children; leaves open durability versus surgery.
Observational (n=14)
Does percutaneous pulmonary valve implantation improve hemodynamics in children with dysfunctional surgically implanted bioprosthetic valves in the RVOT?
Absolute Event Rate: 59.4% vs 82.2%
p-value: p=< 0.001
Percutaneous pulmonary valve implantation is feasible and safe for treating RVOT dysfunction in previously implanted bioprosthetic valves in children, yielding significant short-term hemodynamic improvements.
Asoh et al. (2010) conducted an observational in Right ventricular outflow tract bioprosthetic valve dysfunction (n=14). Percutaneous pulmonary valve implantation vs. Baseline (pre-implantation) was evaluated on Right ventricular pressure at 24 hours (p=< 0.001). Percutaneous pulmonary valve implantation in dysfunctional bioprosthetic valves significantly reduced right ventricular pressure from 82.2 to 59.4 mmHg (P<0.001) at 24 hours.